Literature DB >> 12838286

A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cell dose.

M P Sormani1, R Oneto, B Bruno, M Fiorone, T Lamparelli, F Gualandi, A M Raiola, A Dominietto, M T Van Lint, F Frassoni, P Bruzzi, A Bacigalupo.   

Abstract

We have previously described a scoring system for patients undergoing hemopoietic stem cell transplantation (HSCT) based on day +7 blood urea nitrogen (BUN) and serum bilirubin levels. We have revised that scoring system using a formal multivariate approach based on a training phase (305 patients) and a validation phase (217 patients). Day +7 BUN, serum cholinesterase (CHE), total proteins (TP), gamma glutamyl transferase (gammaGT), donor type and cell dose at transplant were included in the new score. The score distribution identified three groups of patients in the training set (<25, 25-75, >75 percentile of the score) which were classified as low, intermediate and high risk. Their actuarial risk of transplant-related mortality (TRM) at 6 years was, respectively, 12, 38 and 60%. In the validation set the 6 year actuarial TRM was, respectively, 15, 40 and 69%. High risk patients had more graft-versus-host disease (GvHD) (P <0.0001) and lower platelet counts (P <0.0001). This study confirms that GvHD and TRM can be predicted on day +7 after HSCT: pre-emptive GvHD therapy may be one option for high-risk patients and is being tested in a prospective randomized trial. The score for single patients can be calculated on the web site http://213.26.110.20/lrm/day_seven_score.html.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12838286     DOI: 10.1038/sj.bmt.1704085

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew R Rezvani; Barry E Storer; Rainer F Storb; Marco Mielcarek; David G Maloney; Brenda M Sandmaier; Paul J Martin; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-30       Impact factor: 5.742

2.  Alterations of serum cholinesterase in patients with gastric cancer.

Authors:  Shan-Zhi Gu; Xin-Han Zhao; Ping Quan; Sheng-Bin Li; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 3.  Possible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Shigeo Fuji; Markus Kapp; Hermann Einsele
Journal:  Front Oncol       Date:  2014-04-24       Impact factor: 6.244

Review 4.  New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.

Authors:  Mohamad Mohty; Andrea Bacigalupo; Faouzi Saliba; Andreas Zuckermann; Emmanuel Morelon; Yvon Lebranchu
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  The Gamma Gap and All-Cause Mortality.

Authors:  Stephen P Juraschek; Alison R Moliterno; William Checkley; Edgar R Miller
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

6.  The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation.

Authors:  Elisabetta Metafuni; Irene Maria Cavattoni; Teresa Lamparelli; Anna Maria Raiola; Anna Ghiso; Federica Galaverna; Francesca Gualandi; Carmen Di Grazia; Alida Dominietto; Riccardo Varaldo; Alessio Signori; Patrizia Chiusolo; Federica Sora'; Sabrina Giammarco; Luca Laurenti; Simona Sica; Emanuele Angelucci; Andrea Bacigalupo
Journal:  Blood Adv       Date:  2022-04-12

7.  Dynamic changes in serum cytokine levels and their clinical significance in predicting acute GVHD.

Authors:  Chunyan Zhang; Wenrong Huang; Pengjun Zhang; Qingyi Zhang; Guanghong Guo; Feng Gu; Hua Yang; Yurong Wang; Xueliang Huang; Qian Jia; Yaping Tian
Journal:  Oncotarget       Date:  2017-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.